Physician profile
Douglas E Sutherland
NPI 1235210493
$15,125.89
in general payments reported to CMS, 2019-2025
21 companies · $1,840 in 2025
The $1,840 reported for 2025 was more than what 78% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $28.16 · 2021: $252 · 2022: $57.69 · 2023: $1,682 · 2024: $11K · 2025: $1,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Travel and Lodging: $4,575 · Food and Beverage: $2,807 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Travel and Lodging | $4,575.00 |
| Food and Beverage | $2,807.05 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,464.38 | 2019-2025 | Da Vinci Surgical System |
| Coloplast Corp | $376.12 | 2023-2025 | Torosa, Titan |
| Progenics Pharmaceuticals, INC. | $241.36 | 2024-2025 | |
| Edap Technomed INC | $201.20 | 2023 | |
| Procept Biorobotics Corporation | $186.47 | 2023 | Aquabeam Robotic System |
| Medtronic, INC. | $159.02 | 2021 | |
| Urogen Pharma, INC. | $64.04 | 2021-2025 | |
| Novo Nordisk INC | $61.29 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $55.47 | 2024 | Lynparza |
| Myovant Sciences INC. | $50.97 | 2021 | |
| 180 Medical, INC. | $45.18 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $39.93 | 2019 | |
| Allergan, INC. | $34.99 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $25.88 | 2024 | Bard Urinary Drainage Bag |
| Laborie Medical Technologies Corp. | $24.51 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $21.34 | 2019 | |
| Pfizer INC. | $20.61 | 2019 | |
| Astellas Pharma US INC | $16.90 | 2019 | |
| Boston Scientific Corporation | $16.84 | 2019 | |
| Antares Pharma, INC. | $15.57 | 2021 | |
| Travere Therapeutics, INC. | $3.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.